Advanced Treatment Strategies in Prostate Cancer: A Closer Look at the Current and Emerging Therapeutic Options

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2021 – August 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Astellas and Pfizer, Inc., AstraZeneca, and Merck Sharp & Dohme Corp.

Description:
Prostate cancer is the most diagnosed non-cutaneous cancer in men in the United States (US) and remains the second leading cause of cancer deaths among American men, with an estimated 191,930 new cases diagnosed in 2020. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. About 40 percent of these patients have prostate cancer that is also associated with a rising prostate-specific antigen (PSA) level that has not spread to other parts of the body. The danger that can occur, if not caught early, is that 33% of those men could have the cancer spread to other parts of the body.

Patients with all stages of prostate cancer have many treatment options available to them, from front-line therapy to second-line therapy and beyond with both immunotherapy and chemotherapy as current options. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with prostate cancer have been produced and are being used to better treat the disease. The measurement of PSA level has also recently improved the diagnosis of prostate cancer, which is important because it helps identify patients who have prostate cancer and prevent undertreatment. This marker is used for early diagnosis and monitoring for disease recurrence. PSA is the most common biochemical marker for prostate cancer and is used as a screening tool, although it remains prostate specific and not necessarily prostate cancer specific.

Upon completion of this activity, participants will be able to:

  • Implement guideline-recommended treatment strategies to address unmet needs for patients with prostate cancer

  • Assess optimal diagnostic strategies using biomarkers to guide treatment selection in prostate cancer

  • Discuss clinical evidence and data to determine personalized treatment strategies based on patient preferences and efficacy and safety of available treatments

  • Explore the recent evidence supporting PARP inhibitor treatment in prostate cancer

  • Analyze strategies to identify and manage adverse events associated with current and emerging therapies for prostate cancer, including the impact of using a multidisciplinary team

  • Examine the managed care considerations of current and emerging treatments by exploring where these agents fit into current prostate cancer management paradigm

     

Faculty: Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine

Disclosure:

Dr. Dreicer has served in a consulting role for Astella, Bayer, Eisai, EMD Serono, Exelixis, Gilead, Infinity, Janssen, Merck, Myovant, Pfizer, Propella, Pavanta, and Veru. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Astellas and Pfizer, Inc., AstraZeneca, and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue